Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies

Characteristics Value
Number of patients 102
Observation period, days, median [range] 733 [153–3278]
Age, years, median [range] 69 [34–89]
Sex (men), n (%) 70 (68.6)
BMI in men, kg/m2, median [range] 23.5 [16.2–33.8]
BMI in women, kg/m2, median [range] 23.0 [16.0–37.5]
Baseline L3 SMI in men, cm2/m2, median [range] 47.1 [31.5–64.4]
Baseline L3 SMI in women, cm2/m2, median [range] 36.5 [25.6–55.6]
Etiology, n (%)
 HBV 11 (10.8)
 HCV 50 (49.0)
 NBNC 41 (40.2)
  Alcohol 26 (25.5)
  NASH 7 (6.9)
  PBC 2 (2.0)
  Cryptogenic 6 (5.9)
ALT, U/L, median [range] 37 [9–243]
Total bilirubin, mg/dL, median [range] 1.0 [0.4–3.5]
Albumin, g/dL, median [range] 3.7 [2.0–4.9]
Platelet count, × 104/μL, median [range] 12.1 [2.2–80.9]
Child-Pugh classification (A/B/C), n (%) 68(66.7)/34(33.3)/0(0)
AFP, ng/mL, median [range] 21.8 [1.0–633,900]
TNM stage (I/II/III/IV), n (%) 11(10.8)/22(21.6)/46(45.1)/23(22.5)
Maximum tumor diameter, mm, median [range] 32 [9–198]
Number of tumors (solitary/multiple), n (%) 29(28.4)/73(71.6)
Treatment sessions between CT exams, sessions, median [range] 1 (1–6)
Treatment modality (TACE/TAI/TACE+TAI), n (%) 18(17.6)/25(24.5)/59(57.8)
mRECIST assessment (CR/PR/SD/PD), n (%) 18(17.6)/26(25.5)/9(8.8)/49(48.0)
BCAA supplementation (presence/absence), n (%) 72(70.6)/30(29.4)
Cause of death (liver-related/infection/GI bleeding/others/unknown), n 57/7/2/4/2
  1. BMI body mass index, L3 SMI skeletal muscle index at third lumber vertebral level, HBV hepatitis B virus, HCV hepatitis C virus, NBNC non-B non-C, NASH non-alcoholic steatohepatitis, PBC primary biliary cholangitis, ALT alanine aminotransferase, AFP alpha-fetoprotein, TACE transcatheter arterial chemoembolization, TAI transcatheter arterial infusion chemotherapy, mRECIST Modified Response Evaluation Criteria in Solid Tumors, CR complete response, PR partial response, SD stable disease, PD progressive disease, BCAA branched-chain amino acid, GI gastrointestinal